Abstract
Introduction
Ovarian cancer accounts for the highest tumour-related mortality of all gynaecologic malignancies and is a common cancer in women [1] . There are an estimated number of 14 600 deaths due to this disease each year in the US [2] . Despite radical surgery and adjuvant systemic chemotherapy, the majority of patients develop recurrent disease and eventually die of their disease [3] . Although primary cytoreductive surgery is well accepted as the crucial step of initial therapy and residual tumour after primary surgery is considered the most important prognostic factor, the use of cytoreductive surgery in the setting of recurrent disease is defined less clearly. Several retrospective studies suggest a benefit of secondary cytoreduction but until today, no data from randomized phase 3 trials is available [4, 5] . Most retrospective analyses report improved survival in patients with complete secondary debulking (no residual tumour), while the role of so-called 'optimal debulking' (residual tumour <1cm) for recurrent disease remains controversial [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Despite these results, surgical therapy still plays only a minor role in the treatment of recurrent ovarian cancer in clinical routine. Besides the lack of conclusive evidence this might also be caused by the technical complexity of secondary surgery in patients with repetitive abdominal procedures.
Information regarding the feasibility and perioperative outcome of these surgical procedures is very limited. In most of the published retrospective studies, surgical procedures, perioperative morbidity and mortality were not reported systematically [11] .
We conducted the current study to determine the surgical procedures and complications of secondary cytoreduction and evaluate the accomplishment of optimal surgical results in recurrent ovarian cancer compared to primary surgery.
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Patients and Methods
Patients
All patients with advanced primary (stage III and IV) or relapsed epithelial ovarian cancer who presented for surgery at the University Medical Center Hamburg-Eppendorf between 1996 and 2004 were retrospectively analysed. Patients with ovarian carcinoma of low malignant potential (borderline tumours) and patients who underwent surgery solely for the correction of bowel obstruction were excluded from the analysis.
Altogether 222 patients were analysed in this study, including 48 patients with relapsed and 174 patients with primary ovarian cancer. In case of recurrent disease, patients who were considered to have resectable disease underwent an attempt for secondary cytoreduction. This was defined as surgery with the intent to resect all visible tumour. If complete tumour resection was appeared achievable, systematic assessment of the retroperitoneum was performed during secondary surgeries. In case of enlarged lymph nodes, a radical pelvicparaaortic lymphadenectomy was performed only in patients who did not undergo this procedure during primary surgery. Otherwise only enlarged lymph nodes were excised. All patients received prophylaxis for thromboembolism with low-molecular weight heparin (Enoxaparin-Natrium 20 and 40mg) from the day before surgery until at least ten days after surgery. The decision to attempt secondary cytoreduction was based on the results of clinical examination, previous therapies and performance status of the patient on an individual basis.
Additional radiologic examinations were performed if necessary, but despite vaginal ultrasound, no routine test was performed. All cases were discussed at an interdisciplinary tumour board consisting of gynaecologic oncologists, medical oncologists, radiologists, pathologists and surgical oncologists.
Data was retrieved from patients' records, the tumour registry and death certificates; all patients were followed from the date of surgery until death or the date of last follow up for patients who remained alive. Written informed consent was obtained from all patients to [17] .
Analysis of surgical procedures and outcome
To analyse the feasibility of secondary cytoreduction and the accomplishment of complete tumour resection, surgical reports were systematically reviewed for localisation of the main tumour mass, performed procedures, duration of surgery and result of cytoreduction. To evaluate perioperative morbidity, the number of transfused blood products, the days on intensive care unit and the time of in hospital care as well as the frequency of specific complications (including postoperative infections (urinary/wound/abdominal), septicemia, temperature > 38,5°C after surgery, fever > 6 days after surgery, intraoperative and postoperative bowel perforation, enterostomy, postoperative diarrhea, ileus or subileus, postoperative peripheral neuropathy, decubitus, delayed wound healing or wound breakdown, deep vein thrombosis, postoperative pneumothorax or pleural effusion, pulmonary embolism, development of lymphatic cysts, postoperative hemorrhage, renal failure, myocardial ischemia and death within 30 days after surgery) were analysed.
Statistical analysis
All statistical analyses were conducted using SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA). P-values less than 0.05 were regarded as statistically significant. Analysis of potential prognostic factors was performed with the log-rank test for categorical factors and the Cox Proportional Hazards Model for continuous factors. Logistic regression was used to identify potential predictive factors for a higher complication rate in secondary surgeries.
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Results
Patients
A total of 222 patients were analysed in the study, including 48 patients with relapsed ovarian cancer and 174 with primary disease. Detailed patient characteristics are listed in Table I .
Median age was 60 years (range 30-78 years) and. Median relapse-free survival for patients with recurrent disease before secondary cytoreduction was 18 months (range 5-100 months).
There were nine patients with initial FIGO-stage I-IIc included in the analysis of secondary debulking. Median time to recurrence (initial surgery until recurrence and secondary surgery) in this cohort was 15 months (5-71). Twenty-eight (58%) of the 48 patients with disease recurrence had no residual disease after primary surgery and 42 (87%) residual disease <1cm.
Thirty-two (67 %) of the patients had received primary surgery in our institution as well. All patients underwent secondary cytoreduction with the intent to resect all visible disease. They were compared to 174 patients with advanced ovarian cancer (stage III or IV disease) undergoing primary cytoreduction during the same period. Median age in this group was 61 years (range 26-87 years).
Surgical procedures performed are listed in Table II . The rate of upper abdominal interventions (including splenectomy, gastric-/ hepatic-and pancreatic resections) was similar in secondary and primary surgeries. 43% of the patients with relapsed and 62% of the patients with primary ovarian cancer underwent bowel resection. An enterostomy was necessary in 6% of the primary cases and 2% of the cases with relapsed disease. Systematic radical pelvic and paraaortic lymphadenectomy was performed in 73% of the primary cytoreductions and in 39% of secondary surgeries. Table III lists the localisation of recurrent disease at secondary cytoreduction: Leading site of relapsed disease was the intestine including the mesenterium. Some patients did not undergo complete intraabdominal exploration; to reach a higher precision in recurrence localisation we classified these patients 
Surgical outcome and morbidity
In 23 of 48 (48%) of secondary cytoreductions so called 'optimal surgical results' (residual disease <1cm) were obtained compared to 143 of 174 (82%) at primary cytoreduction (Table   II) . 33% of the patients had no residual tumour after secondary cytoreduction versus 58% after primary debulking. There was no correlation between the surgical result of primary and secondary cytoreduction in patients with relapsed disease. Median operating time was significantly shorter at secondary cytoreduction (225 versus 340 minutes for secondary versus primary surgery) and significantly less blood products were transfused (p<0.001 and p=0.001) (median number of fresh frozen plasma units 3 versus 10; packed red blood cell units 4 versus 5, (Table II) . The duration of inhospital care was 3 days longer after surgery for recurrent disease although the need of intensive care was similar to primary surgery (Table II) .
A list of perioperative complications at primary and secondary cytoreductive surgery is shown in Figure 1 . There were no significant differences in overall complication rates between the two groups with a overall complication rate of 44% for secondary and 36% for primary surgery. The number of intestinal injuries was higher in secondary surgeries (3/48 patients versus 0/174 in primary cytoreduction), as well as the number of prolonged subileus after surgery (3/48 patients versus 2/174 after primary cytoreduction). One patient died of pulmonary embolism shortly after secondary cytoreduction. In the subgroup of patients with initial FIGO stage I-IIc undergoing secondary surgery for recurrent disease, perioperative complication rates were as follows: 5 patients (56%) had no complications, 2 patients had 1 complication (bowel injury; urinary tract infection) and 2 patients had 2 complications (bowel injury and postoperative hemorrhage; bowel injury and postoperative pleural effusion). (Table IV) .
Survival analysis
The median time to progression after secondary surgery was 22 months (range 1-100 months), and median overall survival was 26 months (Table II) (range 1-100 months). Thirty-two of the 48 patients (67%) who underwent secondary cytoreductive surgery developed another recurrence during follow up, and 26 patients (54%) died. In the subgroup of patients with initial FIGO-stage I-IIc, median progression-free survival after secondary surgery was 14 months (1-85) with a corresponding median overall survival of 28 months (4-85), respectively.
The predictive value of bowel-, upper abdominal-and/or diaphragmal resection for survival was analysed using the Cox Proportional Hazards Model. None of the variables showed an influence on disease free or overall survival, neither did the occurrence of one or more complication during or after secondary surgery (p=0.33 and p=0.58).
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Discussion
Although cytoreductive surgery is well established in the primary management of ovarian cancer, the use of secondary cytoreduction in the setting of recurrent disease is defined less clearly. Since most of the patients will eventually experience relapsed disease and residual tumour after primary surgery is considered the most important prognostic factor, a second cytoreductive approach in addition to second line chemotherapy appears to be a logical approach. The availability of clinical data regarding resection rates and perioperative morbidity is an important cornerstone of decision making and patient counselling. There is some evidence that selected patients with relapsed disease ovarian cancer will benefit from surgical efforts when optimal surgical results are achieved [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, the lack of criteria for patient selection and the technical complexity of these procedures cause reluctance to perform secondary surgery. To determine the perioperative outcome of secondary debulking surgery and the accomplishment of complete cytoreduction in recurrent ovarian cancer we analysed 48 patients with relapsed epithelial ovarian cancer who presented for surgery at our institution. Surgical procedures and outcome were compared to 174 patients undergoing primary cytoreductive surgery during the same time period.
Tumour resection rates
Complete tumour resection could be achieved in 16 of 48 33% of the patients with recurrent ovarian cancer. Twenty-three of 48 48% of patients that had residual disease of less than 10 mm in greatest diameter. At primary surgery, complete resection rate was 101/174 58% and 143/174 82% of the patients had residual tumour of less than 1 cm. These resection rates are in line with previous reports: Harter et al. reviewed 17 studies on secondary cytoreduction in relapsed ovarian cancer and found a complete tumour resection rate of 9-82% [11] . The proportion of patients with complete tumour resection in secondary cytoreductive surgery is generally smaller than in primary surgeries, which could be caused by the localisation of recurrent disease, often spreading along the small bowel and mesenterium [13, 18] . However,
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10 the published retrospective studies are difficult to compare because of different patient selection criteria and consecutive selection bias.
Perioperative morbidity and mortality
The surgery-related morbidity and mortality we observed in patients with secondary cytoreduction for recurrent disease was similar to patients with primary debulking surgery for advanced ovarian cancer: One patient died of pulmonary embolism after secondary cytoreduction and the overall perioperative morbidity rate was 44%, compared to 36% in patients undergoing primary surgery. The mortality rate of secondary cytoreduction reported in the literature ranges between 0 and 3% and includes death due to septic shock, pulmonary embolism and multiple organ failure [6, 7, 11, 16, 19] . Peri-and postoperative morbidity rates range from 8 to 52% [6, 16] . In general, previously published morbidity and mortality rates of other studies on secondary cytoreduction are in the same range as those reported for primary surgery, but were not reported systematically [5] [6] [7] [8] [9] [11] [12] [13] [14] [15] [16] [19] [20] [21] [22] .
The most common complications of secondary cytoreductive surgery in our cohort were postoperative hemorrhage, intraoperative bowel injury, prolonged postoperative subileus and delayed wound healing (6% each). The increased rate of intraoperative bowel injuries in secondary cytoreductions we observed has previously been described by Scarabelli et al. and Chi et al. [13, 18] . A possible explanation could be the increased risk of intestinal injuries due to adhesions after primary debulking surgery. To achieve complete tumour resection in ovarian cancer it is often necessary to perform bowel resection. In our study, 21/48 patients (43%) underwent bowel resection at secondary cytoreduction compared to 108/174 62% at primary surgery; an enterostomy was necessary in one patient. Bowel resection had no impact on the complication rate or survival of our patients. The rate of bowel resections at secondary cytoreductive surgery varies widely in literature and ranges between 10% and 88%. Again, cross-trial comparison is difficult due to differences in patient selection [8, 16] .
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In contrast to other series, we could not observe a higher rate of upper abdominal procedures at secondary cytoreduction compared to primary surgery [21] . The proportion of splenectomy, hepatic-, pancreatic-or gastric resections was similar in both groups. However diaphragmal resection was performed more frequently at primary cytoreductive surgery (41% versus 16%). This is in line with the documented localisation of recurent disease in our population (Table   III) . If the peritoneum of the diaphragm has been properly resected at primary surgery, it is usually not affected at disease recurrence to our experience. None of the procedures affecting the upper abdomen was associated with a higher complication rate or unfavourable outcome of secondary cytoreduction. Neither were age, FIGO stage at primary diagnosis or other surgical procedures (bowel resection, lymphadenectomy, Table IV ).
The median duration of surgery for recurrent disease in our cohort was two hours less than for primary ovarian cancer. Also, the amount of transfused blood products was lower. This effect could partially be explained by the usually higher rate of extensive peritonectomy and systematic lymphadenectomy at primary surgery compared to relapsed disease. Another aspect might be a more focused approach at secondary cytoreduction towards isolated sites of recurrence, compared to the standardized procedures of primary debulking surgery including hysterectomy, adnectomy, omentectomy, resection of the peritoneum and systematic lymphadenectomy.
Limitations of our study are its retrospective and monocentric nature as well as non standardised selection criteria for patients undergoing secondary cytoreductive surgery.
However, the high number of patients with ovarian cancer treated at our institution and the uniform treatment by a specialised surgical and oncological team might be a strength of this study, as inter-patient-variability in peri-surgical management was very low.
Conclusion
In conclusion Our study suggests that secondary cytoreductive surgery for recurrent epithelial ovarian cancer can be accomplished with a similar complication rate, morbidity and mortality 
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